Cost-Effectiveness Analysis of the Messenger RNA Test (Aptima®) Compared With the Polymerase Chain Reaction DNA Test for Human Papillomavirus Screening From the Colombian Perspective

Key Points

• This analysis aims to evaluate the cost-effectiveness of the Aptima test relative to the PCR DNA test for HPV screening.
• Comparative cost-effectiveness analysis based on screening strategies
• Focus on women over 30 years old
• Contextual analysis within the Colombian health system
• Aptima test demonstrates increased cost-effectiveness compared to PCR, improving screening efficiency
• Implementation of the Aptima test can optimize resource allocation in HPV prevention
• Overall reduction in long-term healthcare costs associated with HPV-related conditions